

Prostate Sarcoma – A Diagnostic Challenge Initially Suspected as Prostatitis

David Weiss¹, Arne Bischoff¹, Tariq Takla², Verena Mack¹, Martin H. Maurer^{1*}

¹ Department of Diagnostic and Interventional Radiology, University Medicine Oldenburg, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany

² Department of Urology, University Medicine Oldenburg, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany

Corresponding author: Martin H. Maurer · martin.maurer@uol.de

ORCID: [0000-0003-0153-3987](https://orcid.org/0000-0003-0153-3987)

Received: 05 June 2025 · Published: 20 June 2025

Swiss Journal of Radiology and Nuclear Medicine · SJORANM GmbH · Rosenweg 3, CH-6340 Baar, Switzerland

Keywords: Prostatic sarcoma; infiltrative unstable, partially CD34+ sarcoma; atypical or refractory urological symptoms

Abstract

Prostatic sarcoma can mimic benign urological disease and delay diagnosis. A 42-year-old man presented with urinary symptoms and pelvic pain and was initially treated for suspected prostatitis. CT and multiparametric MRI demonstrated an extensive prostatic mass with adjacent-organ invasion and obstructive uropathy. Histopathological evaluation subsequently established a partially CD34-positive sarcoma without further classification; staging revealed hepatic metastases. Doxorubicin and ifosfamide produced an initial partial response, followed by pelvic exenteration. Local recurrence and metastatic progression subsequently occurred despite gemcitabine/docetaxel and pazopanib. The patient died in June 2023. This case highlights the diagnostic value of imaging and tissue assessment in atypical or persistent urological presentations and the aggressive clinical course that may occur despite multidisciplinary treatment.

Introduction

Prostatic sarcomas are rare and aggressive malignancies, often presenting with nonspecific symptoms that mimic benign urological conditions, potentially leading to diagnostic delays [1]. This case outlines the clinical course of a 42-year-old male with a prostatic sarcoma, emphasizing the importance of early imaging, histopathological assessment, and multidisciplinary oncological management.

Case Presentation

A 42-year-old male initially presented to the emergency department in July 2022 with new-onset flank pain. He had been experiencing progressive lower abdominal pain, dysuria, weakened urinary stream, and intermittent discomfort in the rectal region for 3 months. He denied any macroscopic hematuria but reported increased urinary frequency and dysuria occurring multiple times especially at night.

Case Presentation (continued)

An initial diagnostic imaging with low-dose CT scan of the abdomen and pelvis revealed an inhomogeneous intrapelvic mass partially involving the prostatic lodge, along with a 6 mm calculus in the distal left ureter (Fig. 1A) resulting in Grade I hydronephrosis (Fig. 1B). A transrectal prostate biopsy was performed, which initially failed to confirm malignancy but demonstrated a partially necrotic, myxoid mesenchymal proliferation. Immunohistochemical analysis was initiated, and empirical antibiotic therapy was commenced under the provisional diagnosis of prostatitis. PSA levels remained within normal ranges.

Multiparametric MRI of the prostate revealed a T2-weighted hyperintense (Fig. 2A, B), vivid contrast-enhancing lesion (Fig. 2C) with diffusion restriction (Fig. 2D) and infiltration of the urinary bladder including the left ureteral orifice, resulting in obstructive uropathy and hydronephrosis. In July 2022, bilateral ureteral stents were placed without complication, and the patient was temporarily discharged into outpatient care.



Figure 1. Unenhanced abdominal CT shows an extensive mass in the prostatic fossa and a calculus in the distal left prevesical ureter (arrow, A), with grade I hydronephrosis of the left kidney (arrow, B).

In August 2022, follow-up reports from the pathology department confirmed the diagnosis of infiltrative unstable, partially CD34 + sarcoma without further characterisation and classification.

In the same month, the patient was referred for extended oncological evaluation, including staging imaging with CT and liver MRI, which confirmed the presence of hepatic metastases resulting in a pT3 pN0 M1, stage IV.

On August 12, 2022, a central venous port was implanted, and systemic chemotherapy was initiated with doxorubicin on day 1 and ifosfamide from day 1 to day 5 [4, 5]. Restaging in October 2022 demonstrated a partial therapeutic response, with regression of both the primary pelvic mass and hepatic lesions.

Given the favorable interim response, the multidisciplinary tumor board recommended surgical management. The patient subsequently underwent an en-bloc pelvic exenteration in December 2022, including resection of the rectum, urinary bladder, and prostate, along with urinary diversion via an ileal conduit and bilateral Mono-J ureteral stent placement. Initial postoperative recovery was uneventful.




Figure 2. Extensive prostatic mass (A, axial T2-weighted image) with extracapsular extension (B, sagittal T2-weighted image), strong contrast enhancement and seminal vesicle infiltration (C), and restricted diffusion on the ADC map (D).

Clinical Course and Outcome

During routine follow-up in February 2023, imaging confirmed tumor progression, showing local recurrence, pelvic wall infiltration, involvement of the lateral limb of the right adrenal gland, worsening hepatic metastases, and the emergence of new pulmonary metastases. The patient was started on palliative chemotherapy with gemcitabine and docetaxel [6]. However, follow-up imaging in April 2023 demonstrated further tumor progression, prompting a change in systemic therapy to pazopanib.

On May 20, 2023, the patient presented with a scrotal abscess, suspected to be secondary to intrapelvic tumor progression with associated small bowel perforation.

Management included surgical drainage of the abscess, CT-guided placement of a drainage system and initiation of intravenous antibiotic therapy with meropenem. Despite these interventions, the patient's clinical status continued to decline. Unfortunately the patient passed away on June 1, 2023.

Discussion

This case illustrates the complex clinical trajectory of rare primary prostate sarcoma, initially misdiagnosed due to overlapping features with benign urological conditions. Prostate sarcomas present a diagnostic and therapeutic challenge due to their rarity and nonspecific presentation [1, 2, 3]. In this case, early use of diagnostic imaging and histopathological biopsy was crucial for establishing an accurate diagnosis. Timely oncological referral and coordinated multidisciplinary care were instrumental in initiating an appropriate treatment plan. The patient received systemic chemotherapy followed by radical surgical resection, resulting in an initial favorable clinical response. However, despite comprehensive treatment, the disease demonstrated aggressive behavior, with rapid progression and early metastasis. As reflected in the literature, the overall prognosis for prostate sarcomas remains poor [1, 3], even with multimodal therapy. General soft tissue sarcoma survival statistics [7] are not specific to prostate sarcoma.

Conclusion

This case underscores the importance of maintaining a high index of suspicion in patients with atypical or refractory urological symptoms. It also highlights the critical role of a multidisciplinary approach, encompassing urology, oncology, radiology, and pathology, in managing such rare malignancies. Ultimately, the case emphasizes the ongoing need for novel and more effective systemic therapies to improve outcomes.

Declarations

Consent for publication: The author clarifies that written informed consent was obtained and the anonymity of the patient was ensured. This study submitted to Swiss J. Radiol. Nucl. Med. has been conducted in accordance with the Declaration of Helsinki and according to requirements of all applicable local and international standards.

Competing interests: No competing interests. The authors declare that there were no conflicts of interest within the meaning of the recommendations of the International Committee of Medical Journal Editors when the article was written.

Funding: No funding resources.

Data availability: All data generated or analyzed during this study are available from the corresponding author upon reasonable request. The datasets supporting the conclusions of this article have been securely archived and can be accessed for further assessment, subject to ethical and legal considerations. This work has been published in the Swiss Journal of Radiology and Nuclear Medicine.

Correspondence: Prof. Dr. Dr. med. Martin H. Maurer, Director, Department of Diagnostic and Interventional Radiology, University Medicine Oldenburg, University of Oldenburg, Rahel-Straus-Str. 10, 26133 Oldenburg, Germany. Telephone: +49 441 403 72520. Email: martin.maurer@uol.de.

References

1. Herlemann A, Horst D, D'Anastasi M, Kretschmer A, Stief CG, Gratzke C. Das primäre Prostatasarkom – ein seltenes Malignom. *Der Urologe*. 2017;56(7):857–860. <https://doi.org/10.1007/s00120-017-0370-z>
2. Alfaro-Cervelló C, Nieto G, Navarro S. Differential diagnosis of myxoid soft tissue tumors. Experience in the Clinical University Hospital of Valencia. *Revista Española de Patología*. 2022;55(3):185–191. <https://doi.org/10.1016/j.patol.2019.07.005>
3. Yang W, Liu A, Wu J, Niu M. Prostatic stromal sarcoma. *Medicine*. 2018;97(18):e0495. <https://doi.org/10.1097/MD.00000000000010495>
4. Steen S, Stephenson G. Current treatment of soft tissue sarcoma. *Baylor University Medical Center Proceedings*. 2008;21(4):392–396. <https://doi.org/10.1080/08998280.2008.11928435>
5. American Cancer Society. Chemotherapy for Soft Tissue Sarcomas [Internet]. <https://www.cancer.org/cancer/types/soft-tissue-sarcoma/treating/chemotherapy.html>
6. Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. *The Oncologist*. 2007;12(8):999–1006. <https://doi.org/10.1634/theoncologist.12-8-999>
7. Sarcoma UK. Soft tissue sarcoma survival [Internet]. 2024 [cited 2025 Apr 21]. <https://sarcoma.org.uk/about-sarcoma/soft-tissue-sarcoma-data-hub/soft-tissue-sarcoma-survival/>

License and Publisher's Note

This work is licensed under the Creative Commons Attribution 4.0 International License. This license requires that reusers give credit to the creator. It permits distribution, remixing, adaptation and reuse in any medium or format, including commercial use.

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Swiss J. Radiol. Nucl. Med. and/or the editor(s). Swiss J. Radiol. Nucl. Med. and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Digital Article: sjoranj.com/sjoranj/article/view/66

Editorial correction: 16 September 2026. Figure cross-references, abstract, bibliographic details and presentation updated; original publication date and pagination retained.